Acrolein target-linked toxicological perturbation and tumor-immune microenvironment heterogeneity in colorectal cancer
- 1Department of Gastrointestinal Surgery, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine
Abstract
Background: Acrolein is a highly reactive aldehyde generated endogenously during lipid peroxidation and encountered through environmental and dietary exposures. Although acrolein has established electrophilic, genotoxic, and oxidative-stress effects, the extent to which acrolein-linked gene perturbation is represented in colorectal cancer (CRC) transcriptomes and relates to tumor immune-stromal heterogeneity remains incompletely characterized.
Methods: We integrated direct human acrolein target evidence from the Comparative Toxicogenomics Database (CTD) with TCGA-COAD/READ bulk RNA-sequencing profiles and a single-cell RNA-sequencing subset from GSE231559. The CTD curation yielded 179 unique direct human targets. Bulk analyses included 624 primary-tumor and 51 solid-tissue normal profiles. Single-cell analyses included six tumor and three normal libraries, yielding 24,128 retained cells assigned to eight broad marker-supported compartments. Target dysregulation burden, immune-stromal expression programs, and library-aware single-cell target localization were evaluated as transcriptomic summaries. In addition, RT-qPCR was performed in HCT 116 colorectal carcinoma cells to experimentally evaluate four measurable CTD targets (NFKBIA, GSTP1, VIM, and GPX4) after acrolein exposure.
Results: The bulk tumor-normal analysis identified 5,594 differentially expressed genes at FDR < 0.05 and |log2 fold change| ≥ 1. Of 179 CTD acrolein targets, 155 were measurable in the bulk dataset and 43 met the differential-expression threshold. Mean absolute normal-reference target burden was higher in tumors than normal tissue (1.96 vs. 0.75; difference 1.21; Welch p = 3.62e-42). Within primary tumors, target burden correlated negatively with T-cell and endothelial programs (rho = −0.27 for each), myeloid (rho = −0.20), fibroblast-ECM (rho = −0.19), and antigen-presentation programs (rho = −0.20), and positively with cell cycle (rho = 0.20). In single-cell data, descriptive mean target scores were highest in myeloid cells (0.455), fibroblasts (0.424), and endothelial cells (0.344). Cross-scale effects for 154 shared targets showed modest concordance (rho = 0.31, p = 6.95e-05). RT-qPCR showed vehicle-normalized relative expression of 2.18 ± 0.14 for NFKBIA, 1.83 ± 0.13 for GSTP1, 1.57 ± 0.15 for VIM, and 0.71 ± 0.09 for GPX4 after acrolein exposure (mean ± SD of three biological replicates).
Conclusions: Acrolein target-linked expression perturbation is detectable in CRC and is associated with immune-stromal heterogeneity across bulk and single-cell transcriptomic scales. RT-qPCR provides targeted experimental support for acrolein-responsive expression changes in NFKBIA, GSTP1, VIM, and GPX4 in HCT 116 cells. These findings support a toxicogenomic framework for hypothesis generation but do not measure acrolein exposure in patients, establish causal toxicological effects in human tumors, or demonstrate a specific intercellular signaling mechanism. Additional mechanistic, protein/adduct, dose-response, and independent-cohort validation will be required to determine the biological significance of the observed associations.
Related
- NETs and the thrombo-immune microenvironment: immune heterogeneity in recanalization, reperfusion, hemorrhagic transformation, and antithrombotic strategies
- Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
- Diet-attributable colorectal cancer in Asia: Regional heterogeneity in burden and dietary intake
- Deep learning-based virtual perturbation reveals increasing heterogeneity of gene regulatory responses with aging
- Isoalantolactone exhibits activity against Echinococcus multilocularis associated with mitochondrial perturbation and changes in the lesion microenvironment
BibTeX
@article{cheng2026acrolein,
title = {{Acrolein target-linked toxicological perturbation and tumor-immune microenvironment heterogeneity in colorectal cancer}},
author = {Gongming Cheng and Liuqun Shan and Wenjie Shi and Xucheng Liu and Xuewen Tao and Jianbo Han},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1929802},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1929802/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Acrolein target-linked toxicological perturbation and tumor-immune microenvironment heterogeneity in colorectal cancer
AU - Gongming Cheng
AU - Liuqun Shan
AU - Wenjie Shi
AU - Xucheng Liu
AU - Xuewen Tao
AU - Jianbo Han
PY - 2026
DA - 2026/10/14
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1929802
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1929802/full
AB - Background: Acrolein is a highly reactive aldehyde generated endogenously during lipid peroxidation and encountered through environmental and dietary exposures. Although acrolein has established electrophilic, genotoxic, and oxidative-stress effects, the extent to which acrolein-linked gene perturbation is represented in colorectal cancer (CRC) transcriptomes and relates to tumor immune-stromal heterogeneity remains incompletely characterized. Methods: We integrated direct human acrolein target evidence from the Comparative Toxicogenomics Database (CTD) with TCGA-COAD/READ bulk RNA-sequencing profiles and a single-cell RNA-sequencing subset from GSE231559. The CTD curation yielded 179 unique direct human targets. Bulk analyses included 624 primary-tumor and 51 solid-tissue normal profiles. Single-cell analyses included six tumor and three normal libraries, yielding 24,128 retained cells assigned to eight broad marker-supported compartments. Target dysregulation burden, immune-stromal expression programs, and library-aware single-cell target localization were evaluated as transcriptomic summaries. In addition, RT-qPCR was performed in HCT 116 colorectal carcinoma cells to experimentally evaluate four measurable CTD targets (NFKBIA, GSTP1, VIM, and GPX4) after acrolein exposure. Results: The bulk tumor-normal analysis identified 5,594 differentially expressed genes at FDR < 0.05 and |log2 fold change| ≥ 1. Of 179 CTD acrolein targets, 155 were measurable in the bulk dataset and 43 met the differential-expression threshold. Mean absolute normal-reference target burden was higher in tumors than normal tissue (1.96 vs. 0.75; difference 1.21; Welch p = 3.62e-42). Within primary tumors, target burden correlated negatively with T-cell and endothelial programs (rho = −0.27 for each), myeloid (rho = −0.20), fibroblast-ECM (rho = −0.19), and antigen-presentation programs (rho = −0.20), and positively with cell cycle (rho = 0.20). In single-cell data, descriptive mean target scores were highest in myeloid cells (0.455), fibroblasts (0.424), and endothelial cells (0.344). Cross-scale effects for 154 shared targets showed modest concordance (rho = 0.31, p = 6.95e-05). RT-qPCR showed vehicle-normalized relative expression of 2.18 ± 0.14 for NFKBIA, 1.83 ± 0.13 for GSTP1, 1.57 ± 0.15 for VIM, and 0.71 ± 0.09 for GPX4 after acrolein exposure (mean ± SD of three biological replicates). Conclusions: Acrolein target-linked expression perturbation is detectable in CRC and is associated with immune-stromal heterogeneity across bulk and single-cell transcriptomic scales. RT-qPCR provides targeted experimental support for acrolein-responsive expression changes in NFKBIA, GSTP1, VIM, and GPX4 in HCT 116 cells. These findings support a toxicogenomic framework for hypothesis generation but do not measure acrolein exposure in patients, establish causal toxicological effects in human tumors, or demonstrate a specific intercellular signaling mechanism. Additional mechanistic, protein/adduct, dose-response, and independent-cohort validation will be required to determine the biological significance of the observed associations.
SN - 2297-055X
ER -